CompletedNot Applicable

Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer Patients

France179 participantsStarted 2010-07

Plain-language summary

The T and B cells repertoire diversity represent one of the immune defence level which controls the integrity of the organism and determines its ability to recognize and control infectious attacks and development of tumours. The study of the lymphocytes TCR and BCR diversity could permit to better understand how lymphopenia act on overall survival and to improve detection of high risk patients who could benefit of adapted therapies for better care.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years old, * Patients with an histologically proven, inoperable breast or lung tumour, * Metastatic disease before the start of any chemotherapy, * Signed written informed consent form, * Covered by a medical insurance, * Patient accepting the conservation of biological samples, * Locally advanced incurable disease (only breast tumour). Exclusion Criteria: * Hematological tumour, * Auto-immune disease (including HIV-positive - AIDS stage) or patients with immunosuppressive therapy, * Metastatic disease that had progressed after a first line chemotherapy, * Pregnant or lactating female or female of child-bearing potential not employing adequate contraception, * Patient deprived of liberty by a judicial or administrative, * Adult protected by law.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Analyse the prognostic value of divpenia

Timeframe: 3 month (lung cancer) 6 month (breast cancer)

Trial details

NCT IDNCT01306188

SponsorCentre Leon Berard

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2014-12

View on ClinicalTrials.gov More Breast Cancer trials